Empowering Each Other to Achieve the Extraordinary

At RNATher U1326, we believe that our greatest breakthroughs come from the strength of our team. We foster an environment where each member’s talents and ideas are valued, driving us to push boundaries and reach new heights in RNA research. By supporting and inspiring one another, we unlock our full potential and create transformative solutions in RNA therapeutics. Together, we strive not just for progress, but for the extraordinary.

image

Innovating Precision Nanomedicine to Defeat Prostate Cancer

At RNATher U1326, we are harnessing the power of nanotechnology to create precise, mRNA targeted therapies against prostate cancer. By developing innovative nanomedicines, our research aims to deliver treatment directly to cancer cells, minimizing side effects and enhancing effectiveness. We believe that our pioneering work in nanomedicine has the potential to transform prostate cancer care and improve patients' lives. With each breakthrough, we move closer to a future where prostate cancer is not only treatable but defeatable.

image

Pioneering RNA Therapy for Tomorrow's Cures

At RNATher U1326, we are dedicated to breaking new ground in RNA science to transform the future of medicine. At the crossroads between precision medicine, nucleic acid therapeutics, nanomedicine, and radiotherapy, we focus to develop novel nucleolipids-based nanocarriers for the selective and combined delivery to PC cells of an Antisense Oligonucleotide (targeting specific oncogenes responsible for treatment resistance) and therapeutic radionuclides.

image

Organoids biobank

Developing biobank of organoids derived from prostate cancer patients for precision medicine

Smart nanomedicine

Develop a smart, multifunctionl nanoparticle for theranostics (therapy+diagnostic) in TRPC

New chemo-drugs

Discovery of novel small molecules for TRPC treatment

HSP27 signalling

Gain insights into the mechanisms of action driving TRPC, which are involved in HSP27 signaling

image
About Us

mRNA, Nanomedicine and Theranostic: From cell signaling to personalized therapy

 

Our research interests focus on basic research in cell signalling driving therapeutic- resistant prostate cancer (TRPC), identifications of new therapeutic targets, and development of mRNA-based drugs, with the goal of clinical application in the fields of diagnostic and precision medicine.

 

Discover More
image
Technologies

Our Core Technologies

Antisense Oligonucleotide (ASO)

Innovative Nanomedicine

Molecular Biology

Organoids Biobank

Preclinical drug testing

image
image
Publications

Our Publications

Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs

Communications Biology
23 Apr 2024

Castration-resistant prostate cancer: from uncovered resistance mechanisms to current treatments

Cancers
19 Oct 2023

ZNF703 mRNA-Targeting Antisense Oligonucleotide Blocks Cell Proliferation and Induces Apoptosis in Breast Cancer Cell Lines

Pharmaceutics
11 Jul 2023

Creating overview and summary figures

Trends in Biochemical Sciences
01 Feb 2023

DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer

Molecular Therapy
01 Feb 2023

HSP27/Menin expression as new prognostic serum biomarkers of prostate cancer aggressiveness independent of PSA

Cancers
29 Sep 2022

How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifi…

Progrès en Urologie
01 Jun 2022

How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifi…

Progrès en Urologie
01 Jun 2022

Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity

Oncogene
03 Jan 2022

Antisense oligonucleotide-based therapeutic against menin for triple-negative breast cancer treatment

Biomedicines
08 Jul 2021
Team Members

Our Members

image

Palma ROCCHI, PhD-HDR INSERM Research Director

Laboratory director
image

TAIEB David, PH-PU

Nuclear Medicine, Prof. of Universités – Praticien Hospitalier
image

Laurence COLLEAUX, PhD

DR1 CNRS
image

Michel CAMPLO, PhD

Chemist, MCU/AMU
image

Chemist, MCU-AMU Fred Garzino, PhD

Chemist, MCU-AMU
image

LE Thi Khanh, PhD

Postdoc Researcher
image

TRAN Thi Thom, PhD

IR Biologist, AMU
image

Ines Sousa, Ms

IR Chemist, CNRS
image

Phan Thi Tu Uyen, Ms

Pharmacist/PhD student
image

Galdric Oliver, Medical Oncologist

M2 intern
image

Dr. Michael BABOUDJIAN, Urologist

MD/PhD student
image

DUONG Quang Hieu

Biologist, PhD student
image

Souhaila Zaghdoudi, PhD

Former PhD student
image

Le Thi Thuy, Ms.

Biologist, PhD student
image

Yinghua, Ms

Bachelor Intern
Activities

Our Latest Activities

Happy Birthday, Palma: A Celebration of Our Team Leader!

News
06 Apr 2025

Inserm ERL U1326 unit “RNAnoTher”, led by Dr. Palma Rocchi, created in January 2024, is the first French laboratory to integrate chemical and biological expertise for the production and evaluation of antisense oligonucleotides (ASOs) in precision medicine and radiotheranostics.

Laboratory

Quick Links

Information

  • Phone +33 626941287
  • Email palma.rocchi@inserm.fr
  • Address

    - Marseille Faculty of Medicine CERIMED Bât.10A - 27 Boulevard Jean Moulin - 13005 Marseille

    - CINaM (Centre Interdisciplinaire de Nanoscience de Marseille) UMR 7325, Campus de Luminy, 13009 Marseille

Copyright © 2023 RNAnoTher. All Rights Reserved